Opinion|Videos|October 22, 2024
Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations
Although the NCCN guidelines recommend osimertinib as an adjuvant therapy option, what is your position on its use for completely resected stage IB to IIIA NSCLC with less common EGFR activating mutations, such as exon 20 insertion?
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Although the NCCN guidelines recommend osimertinib as an adjuvant therapy option, what is your position on its use for completely resected stage IB to IIIA NSCLC with less common EGFR activating mutations, such as exon 20 insertion?
Advertisement
Related to this article
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
Conditional approvals in Armenia cover botensilimab plus balstilimab indicated for patients with MSS mCRC without active liver metastases.
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 10/5/2026
2
GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2026
3
Armenia Grants First Marketing Authorizations to Botensilimab Plus Balstilimab in Previously Treated MSS mCRC
4
RYZ101 Meets Primary PFS End Point in Phase 3 ACTION-1 Trial for Post–Lutetium-177 GEP-NETs
5